NCT02691793 is a Phase 4 clinical trial of Sunitinib in Refractory Solid Tumors, sponsored by Samsung Medical Center.

Who is sponsoring NCT02691793?

NCT02691793 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT02691793?

Interventions in NCT02691793: Sunitinib.

What condition does NCT02691793 study?

NCT02691793 studies Refractory Solid Tumors.

Is NCT02691793 still recruiting?

NCT02691793 is currently completed. Last updated 15 June 2022.

Last reviewed 2022-06-15 · How we verify

NCT02691793

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Completed Phase 4 Last updated 15 June 2022

What this trial tests

Phase 4 trial testing Sunitinib in Refractory Solid Tumors in 1 participant. Completed in 19 November 2019.

Timeline

20 November 2017

Primary endpoint
30 August 2019

19 November 2019

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	20 November 2017
Primary completion	30 August 2019
Estimated completion	19 November 2019
Sites	1 location across South Korea

Drugs / interventions tested

Sunitinib (sunitinib) — full drug profile →

Conditions studied

Refractory Solid Tumors — all drugs for Refractory Solid Tumors →

Sponsor

Samsung Medical Center

Who can join

19 and older, any sex, with Refractory Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single arm, pilot study of Sunitinib in patient with RET fusion positive, FGFR2 fusion/FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy. To investigate the efficacy and safety of Sunitinib in patient with Refractory solid tumor.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C, Wei Y, Wei X. · · 2019 · cited 398× · PMID 31684958 · DOI 10.1186/s12943-019-1090-3
FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R, Carneiro BA, Taxter T, Tavora FA, et al · · 2016 · cited 107× · PMID 27409839 · DOI 10.18632/oncotarget.10482
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
Luchini C, Paolino G, Mattiolo P, Piredda ML, et al · · 2020 · cited 75× · PMID 33115526 · DOI 10.1186/s13046-020-01732-6
AXL signaling in cancer: from molecular insights to targeted therapies.
Yadav M, Sharma A, Patne K, Tabasum S, et al · · 2025 · cited 42× · PMID 39924521 · DOI 10.1038/s41392-024-02121-7
Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma.
Williams G, Llewelyn A, Thatcher R, Hardisty KM, et al · · 2022 · cited 3× · PMID 35324914 · DOI 10.1371/journal.pone.0245817
Utilisation of semiconductor sequencing for detection of actionable fusions in solid tumours.
Loddo M, Hardisty KM, Llewelyn A, Haddow T, et al · · 2022 · cited 2× · PMID 35984852 · DOI 10.1371/journal.pone.0246778

Verify or expand the search:

Other trials of Sunitinib

Trials testing the same drug.

NCT07218926 — A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatini · Phase 3 · recruiting
NCT07165418 — A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcino · Phase 3 · not yet recruiting
NCT05773274 — Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroe · Phase 2 · recruiting
NCT05366816 — ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST · Phase 2 · recruiting
NCT06032728 — Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Tre · NA · not yet recruiting

Other recruiting trials for Refractory Solid Tumors

Currently open trials in the same condition.

NCT06150365 — Personalized KSX01-TCRT in Patients With Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT06006273 — A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Sol · Phase 1 · recruiting
NCT05811975 — KSX01-TCRT Injection Project in Solid Tumors · EARLY_PHASE1 · recruiting
NCT05539833 — KSH01-TCRT Solid Tumors · EARLY_PHASE1 · recruiting
NCT03739827 — Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02691793 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 15 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02691793.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing